Posts tagged HCW
HCW ups Fibrocell price target to $7.60

H.C. Wainwright raised its price target for Fibrocell Science (NASDAQ:FCSC) to $7.60 from $5.70 after the company announced first efficacy data from a single injection of FCX-007 in patients with recessive dystrophic epidermolysis bullosa, a congenital and progressive orphan skin disease caused by the deficiency of the protein type VII collagen.

Read More
HCW cuts Applied Genetic price target to $8

H.C. Wainwright slashed its price target for Applied Genetic Technologies (NASDAQ:AGTC) to $8 from $16 but maintained its “buy” rating after the company posted financing results below consensus for the fiscal year ended June 30, 2017 and updated its clinical programs.

Read More
HCW starts Gemphire at buy

H.C. Wainwright launched coverage of Gemphire Therapeutics (NASDAQ:GEMP) with a “buy” rating and a price target of $21, saying it views the sell off in the shares following results of the ROYAL-1 clinical trial as overdone. The stock closed at $9.17 on August 30.

Read More
HCW starts Pharming at buy

H.C. Wainwright launched coverage of  Pharming Group NV (AEX:PHARM) with a “buy” rating and €1.50 price target. The stock was recently quoted at €0.45. 

Read More
HCW starts AzurRx at buy

H.C. Wainwright initiated coverage of AzurRx BioPharma (NASDAQ:AZRX) with a “buy” rating and $8 price target. The stock closed at $4.11 on July 24.

Read More
HCW starts Concert at buy

H.C. Wainwright initiated coverage of Concert Pharmaceuticals (NASDAQ:CNCE) with a “buy” rating and $20 price target. The stock closed at $16.10 on July 24.

Read More
HCW starts Agile Therapeutics at buy

H.C. Wainwright launched coverage of Agile Therapeutics (NASDAQ:AGRX) with a “buy” rating and $10 price target, saying the company is significantly undervalued assuming its Twirla combination hormonal contraceptive (CHC) patch can get FDA approval. The stock closed at $4.93 on July 19.

Read More
HCW downgrades Inotek to neutral

H.C. Wainwright downgraded Inotek Pharmaceuticals (NASDAQ:ITEK) to “neutral” from “buy” and slashed its price target to $2 from $7 after a failed Phase 2 trial. The stock closed at 96 cents on July 11.

Read More
HCW starts Tetraphase at buy

H.C. Wainwright initiated coverage of Tetraphase Pharmaceuticals (NASDAQ:TTPH) with a “buy” rating and $15 price target. The stock closed at $6.88 on July 10.

Read More
HCW starts SeaSpine at buy

H.C. Wainwright initiated coverage of SeaSpine Holdings (NASDAQ:SPNE) with a “buy” rating and 12-month price target of $15. The stock closed at $12.19 on June 7.

Read More
HCW starts Antares Pharma at buy

H.C. Wainwright initiated coverage of Antares Pharma (NASDAQ:ATRS) with a “buy” rating and $5 price target. The stock closed at $3.01 on June 22.

Read More
HCW ups SteadyMed price target to $15

H.C. Wainwright raised its price target for SteadyMed (NASDAQ:STDY) to $15 from $10 after the Patent Trial and Appeal Board ruled in favor of SteadyMed in an inter partes review (IPR) proceeding against United Therapeutics’ 8,497393 patent, finding all 22 claims in the patent unpatentable. The stock closed at $5.80 on March 31.

Read More
HCW upgrades Galectin to buy

H.C. Wainwright upgraded Galectin Therapeutics (NASDAQ:GALT) to “buy” from “neutral” and raised its price target to $3 from 60 cents, citing a more positive view of the therapeutic potential of the mechanism of galectin-3 inhibition. The stock closed at $1.98 on March 29.

Read More